A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Children
A Phase 1, Dose-escalation, Blinded Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Children (9 to <18 Years of Age)
The purpose of this study is to evaluate safety, reactogenicity, and immunogenicity of mRNA-1010 in healthy children (9 to <18 years of age).
調査の概要
研究の種類
入学 (推定)
段階
- フェーズ 1
連絡先と場所
研究連絡先
- 名前:Moderna WeCare Team
- 電話番号:+1-866-663-3762
- メール:WeCareClinicalTrials@modernatx.com
研究場所
-
-
California
-
Modesto、California、アメリカ、95355
- 募集
- Paradigm Clinical Research Centers, LLC
-
-
Colorado
-
Aurora、Colorado、アメリカ、80012
- 募集
- Paradigm Clinical Research Centers, LLC
-
-
Minnesota
-
Minneapolis、Minnesota、アメリカ、55402
- 募集
- Clinical Research Institute, Inc
-
-
Ohio
-
South Euclid、Ohio、アメリカ、44121
- 募集
- Senders Pediatrics
-
-
Texas
-
Houston、Texas、アメリカ、77055
- 募集
- West Houston Clinical Research Service
-
-
Virginia
-
Richmond、Virginia、アメリカ、23226
- 募集
- Clinical Research Partners, LLC.
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- 9 to <18 years of age inclusive, at the time of signing the informed consent/assent.
- In the Investigator's opinion, the participants/participant's parent(s)/legally authorized representative (LAR(s)) demonstrate adequate understanding of the study requirements and are willing and physically able to comply with protocol mandated follow-up, including all procedures.
- For female participants of childbearing potential: negative pregnancy test, adequate contraception or has abstained from all activities that could result in pregnancy for at least 28 days prior to Day 1, and agreement to continue adequate contraception through 90 days following vaccine administration.
Exclusion Criteria:
- History of anaphylaxis or severe hypersensitivity reaction requiring medical intervention after receipt of any mRNA vaccine or therapeutic or any components of an mRNA vaccine or therapeutic; influenza vaccine; or components of influenza vaccine, including egg protein.
- Acutely ill or febrile (temperature ≥38.0 degrees Celsius (℃) [100.4 degrees Fahrenheit [°F]) within 72 hours prior to or at the Screening Visit or Day 1. Participants who are acutely ill or febrile may be scheduled for a separate dosing visit within the window specified for Screening.
- History of a diagnosis or condition not specifically listed as exclusionary that, in the judgment of the Investigator, is clinically unstable, potentially affects participant safety, the assessment of study endpoints, the assessment of immune response, or adherence to study procedures.
- Any prior systemic immunosuppressants, immunomodulators (for example, methotrexate, cyclosporine), or long-acting biological therapies that may affect immune responses (for example, dupilumab, omalizumab). Short courses (<7 days) of oral corticosteroids are allowed if completed at least 3 months prior to Day 1. Inhaled, nasal, topical steroids, and subcutaneous injected allergy immunotherapy (allergy shots) are allowed.
- Received systemic immunoglobulins or blood products within 90 days prior to the Screening Visit or plans to receive them during the study.
- Received any nonstudy vaccine authorized or approved by local health agency within 14 days (28 days for live vaccines and mRNA vaccines) prior to Day 1 (inclusive) or plans to receive any nonstudy vaccine within 28 days post study vaccine administration.
- Donated ≥450 milliliters (mL) of blood products within 28 days prior to the Screening Visit or plans to donate blood products within 28 days post study vaccine administration.
Note: Other protocol-defined inclusion and exclusion criteria may apply.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:防止
- 割り当て:ランダム化
- 介入モデル:順次割り当て
- マスキング:4倍
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:mRNA-1010 Low Dose
Participants will receive a single low dose of mRNA-1010 by intramuscular (IM) injection on Day 1. |
Suspension for injection
他の名前:
|
|
実験的:mRNA-1010 Full Dose
Participants will receive a single full dose of mRNA-1010 by intramuscular (IM) injection on Day 1. |
Suspension for injection
他の名前:
|
|
アクティブコンパレータ:Fluarix Trivalent
Participants will receive a single dose of Fluarix Trivalent by IM injection on Day 1. |
Suspension for injection
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
血球凝集阻害(HAI)アッセイによって測定された、29日目の抗ヘマグルチニン(HA)抗体の幾何平均力価(GMT)
時間枠:29日目
|
29日目
|
|
|
29日目にHAI力価が1:40以上の参加者の割合
時間枠:29日目
|
29日目
|
|
|
要請された局所的および全身的な反応原性有害反応(AR)を有する参加者の数
時間枠:7日目まで(接種後7日)
|
7日目まで(接種後7日)
|
|
|
未承諾の有害事象(AE)のある参加者の数
時間枠:28日目まで(接種後28日)
|
28日目まで(接種後28日)
|
|
|
Number of Participants with AEs Leading to Discontinuation, Serious Adverse Events (SAEs), or Adverse Events of Special Interest (AESI)
時間枠:Day 1 through Day 365
|
Day 1 through Day 365
|
|
|
Number of Participants with Medically Attended AEs (MAAEs)
時間枠:Day 1 through Day 181
|
Day 1 through Day 181
|
|
|
Percentage of Participants Reaching Seroconversion, as Measured by HAI Assay
時間枠:Day 29
|
Seroconversion is defined as either a pre-vaccination HAI titer <1:10 and a post-vaccination titer ≥1:40 or a pre-vaccination HAI titer ≥1:10 and a minimum 4-fold rise in post-vaccination HAI antibody titer. |
Day 29
|
|
Geometric Mean Fold Rise (GMFR) of Anti-HA antibodies, as Measured by HAI Assays
時間枠:Day 29
|
Day 29
|
協力者と研究者
スポンサー
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- mRNA-1010-P102
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。